Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 14;12:617365. doi: 10.3389/fimmu.2021.617365

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 van den Bijgaart, Schuurmans, Fütterer, Verheij, Cornelissen and Adema

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Multifunctional antibody formats for combination with in situ tumor ablation. Administration of 1. bispecific agonistic antibodies (e.g. anti-MSLN-CD40) or 4. antibody-adjuvant fusions (e.g. chTNT3-CpG) will lead to local APC activation. Interventions such as 2. bispecific ICB (e.g. PD-L1xErbB2 antibody) may further stimulate myeloid as well as T cell immunity specifically within the TME; 3. antibody-enzyme fusions allow tumor specific sialoglycan degradation (e.g. anti-HER2 mAb-sialidase); 5. antibody-cytokine fusions (e.g. anti-GD2-IL2) will result in targeted cytokine delivery ensuring local immune cell activation, all are aimed at relieving local immunosuppression.